Thomas Prod’homme

Dr. Prod’homme is the Vice President of Translational Research at Myeloid Therapeutics. He brings over 15 years of experience in pharmacology, IND preparation and early clinical development. Prior to joining Myeloid Therapeutics Dr. Prod’homme served as Senior Director in Translational Medicine at Kiniksa Pharmaceuticals Inc., where he managed target selection, IND-enabling studies, and correlative studies for early clinical trials. Previously, he held several positions of increasing responsibility at Momenta Pharmaceuticals where he was a major contributor to the success of two INDs, including M230, a Selective Immunomodulator of Fc Receptors and M254, a hypersialylated human immunoglobulin G.

Dr. Prod’homme holds a PhD in Immunology from Universite Rene Descartes (Paris 5) and was a postdoctoral fellow in Dr. Scott Zamvil’s laboratory at University of California, San Francisco.

He has authored several patents and published in top-tier scientific journals.